Drugmakers Defend No-Cash Patent Deals Post-Actavis

By Jeff Overley (January 30, 2014, 3:41 PM EST) -- Drugmakers are scrambling to limit the scope of the U.S. Supreme Court's landmark antitrust decision in Federal Trade Commission v. Actavis, arguing with mixed results that the ruling only requires extra scrutiny of deals to delay generic competition if money changed hands....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!